our Premium Content: News alerts, weekly reports and conference planners

GENE:

JAK2 (Janus kinase 2)

News alerts, weekly reports and conference planners

Bone marrow mesenchymal stem cell exosomes suppress JAK/STAT signaling pathway in acute myeloid leukemia in vitro. (PubMed, Blood Res)

Since JAK/STAT signaling contributes to AML survival, our findings suggest that the downregulation of JAK/STAT genes by BM-MSC exosomes in leukemic cells may aid in designing a potent therapeutic strategy for AML treatment.

1 day ago

Preclinical • Journal

JAK2 (Janus kinase 2) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CD9 (CD9 Molecule) • STAT5A (Signal Transducer And Activator Of Transcription 5A) • CD81 (CD81 Molecule)

CD9 expression

Exosomal miR-320d promotes angiogenesis and colorectal cancer metastasis via targeting GNAI1 to affect the JAK2/STAT3 signaling pathway. (PubMed, Cell Death Dis)

Moreover, CRC patients with high levels of miR-320d in their blood respond better to treatment with bevacizumab. In vivo experiments further proved the role of miR-320d from CRC exosomes in increasing tumor size, blood vessel formation, and the spread of cancer to the liver. In this study, we have demonstrated that exosomal miR-320d promotes cancer cell metastasis and enhances angiogenesis by downregulating GNAI1 expression and enhancing JAK2/STAT3.

3 days ago

Journal

JAK2 (Janus kinase 2) • STAT3 (Signal Transducer And Activator Of Transcription 3)

Avastin (bevacizumab)

RUNX1::CBFA2T2 rearranged acute myeloid leukemia transformed from JAK2 V617F mutated primary myelofibrosis. (PubMed, EJHaem)

The immunophenotype and the landscape of cooperative gene alterations in AML with RUNX1::CBFA2T2 resemble those of AML with RUNX1::RUNX1T1, including expression of CD19, cooperative gene alterations in signaling pathway (JAK2), epigenetic/chromatin and cell cycle regulation (TET2, SMC3, and CDKN2A/B), and additional chromosomal abnormalities (trisomies 8 and 15). This case study provides insights into the pathogenesis of this rare subtype of AML.

4 days ago

Journal

CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • JAK2 (Janus kinase 2) • CD19 (CD19 Molecule) • RUNX1 (RUNX Family Transcription Factor 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1)

CD19 expression • JAK2 V617F • JAK2 mutation

Biological Markers of Myeloproliferative Neoplasms in Children, Adolescents and Young Adults. (PubMed, Cancers (Basel))

Although rare, myeloproliferative neoplasms can involve young patients and pose unique challenges for clinicians in diagnosis and therapy. The paper aims to review the biological markers of MPNs in pediatric populations-a particular group of patients that has been poorly studied due to the low frequency of MPN diagnosis.

5 days ago

Review • Journal

IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • JAK2 (Janus kinase 2) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • CALR (Calreticulin)

Classification and Prognostic Stratification Based on Genomic Features in Myelodysplastic and Myeloproliferative Neoplasm- and Their Overlapping Conditions. (PubMed, Cancers (Basel))

Improved survival was observed with transplantation in groups DP2, DP7, and DP9. These findings highlight the role of genomic classifications in guiding personalized treatment strategies, ultimately enhancing the understanding and management of myeloid neoplasms.

5 days ago

Journal

TP53 (Tumor protein P53) • NPM1 (Nucleophosmin 1) • JAK2 (Janus kinase 2) • SF3B1 (Splicing Factor 3b Subunit 1) • SETBP1 (SET Binding Protein 1) • DDX41 (DEAD-Box Helicase 41) • CALR (Calreticulin)

TP53 mutation • NPM1 mutation • SF3B1 mutation • DDX41 mutation • JAK2 mutation • SETBP1 mutation • CALR mutation

Shaping the Future of Myeloproliferative Neoplasm Therapy: Immune-Based Strategies and Targeted Innovations. (PubMed, Cancers (Basel))

These include new JAK inhibitors with greater specificity for JAK2, as well as "add-on" medications designed to enhance the effectiveness of ruxolitinib, in both patients who are new to the drug and in those who have shown suboptimal responses. Additionally, there is ongoing exploration of novel therapeutic targets. In this review, we will explore the immunotherapy approaches that are currently used in clinical practice for MPNs, as well as emerging strategies that are likely to change the treatment of these diseases in the coming years.

5 days ago

Review • Journal • IO biomarker

JAK2 (Janus kinase 2)

Jakafi (ruxolitinib)

Anemia in Myelofibrosis: A Focus on Proactive Management and the Role of Momelotinib. (PubMed, Cancers (Basel))

Summarized are traditional approaches to anemia management and the clinical trial efficacy and safety data that support momelotinib as an option in each setting from mild to severe anemia, including in the context of co-occurring thrombocytopenia. With the availability of momelotinib and other emerging therapies directed at anemia control, early treatment of anemia to avoid progression and support improvement in eligible patients with myelofibrosis should be a primary consideration.

5 days ago

Review • Journal

JAK2 (Janus kinase 2) • JAK1 (Janus Kinase 1) • ACVR1 (Activin A Receptor Type 1)

Ojjaara (momelotinib)

Zuojin Pill Alleviates Precancerous Lesions of Gastric Cancer by Modulating the MEK/ERK/c-Myc Pathway: An Integrated Approach of Network Pharmacology, Molecular Dynamics Simulation, and Experimental Validation. (PubMed, Drug Des Devel Ther)

ZJP downregulated IL-6, TNF-α, c-myc, p-MEK1 and p-ERK1/2, effectively reversing the progression of PLGC. ZJP can reverse MNNG-induced PLGC, potentially through inhibition of the MEK/ERK/c-myc pathway and regulation of cellular proliferation and apoptosis.

5 days ago

Journal

PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • JAK2 (Janus kinase 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • MAPK3 (Mitogen-Activated Protein Kinase 3)

Network pharmacology and molecular docking reveal the mechanism of action of Bergapten against non‑small cell lung cancer. (PubMed, Oncol Lett)

In conclusion, Bergapten exerts its anti-NSCLC effects through the PI3K/AKT pathway, promoting cell senescence and inhibiting inflammation. These findings suggest that Bergapten has potential as a therapeutic agent for NSCLC.

6 days ago

Journal

JAK2 (Janus kinase 2) • TYK2 (Tyrosine Kinase 2)

JAK2 p.R564 germ line variants associated with hereditary thrombocythemia and hematologic neoplasms. (PubMed, Blood Adv)

Identification of germline predisposition is essential to understanding the pathogenesis of disease, impact on families, and opportunities for preventive care. Continued research is essential to further characterize the penetrance of these conditions, and how best to monitor, treat and optimize management for these families.

6 days ago

Journal

JAK2 (Janus kinase 2)

JAK2 V617F • JAK2 mutation

Donor selection for allogeneic hematopoietic cell transplant in a patient with JAK2 V617F primary myelofibrosis and SH2B3/LNK germline variant. (PubMed, Ann Hematol)

The consideration of such inherited traits is crucial for clinical management of patients, particularly with regards to indication for allogeneic hematopoietic cell transplant (allo-HCT) and donor selections. Herein, we describe the very instructive case of a 49-year-old woman diagnosed with JAK2 V617F-positive primary myelofibrosis (PMF) who was found to also carry a germline variant in the SH2B3 gene, detailing clinical management, donor selection process for allo-HCT purposes, and appropriate genetic counseling.

8 days ago

Journal

JAK2 (Janus kinase 2) • SH2B3 (SH2B Adaptor Protein 3)

JAK2 V617F

10d

A comparative retrospective study of pre-fibrotic primary myelofibrosis versus overtly fibrotic stage in Qatar: clinicopathological, genetic landscape, risk stratification and survival data (2008-2021) - a single center experience. (PubMed, Hematology)

To the best of our knowledge our research represents the first and largest published dataset on PMF in MENA region to be published. Merged DIPSS plus scoring came to be a pragmatic tool for defining high-risk patients who significantly differ in mortality, progression, need for treatment and leukemic transformation.

10 days ago

Clinical • Retrospective data • Journal

JAK2 (Janus kinase 2)

JAK2 V617F • JAK2 mutation

11d

Prevalence of JAK 2 v617 Mutations in Malignant and Non-Malignant Tumors in the Eastern Province of the Kingdom of Saudi Arabia. (PubMed, Clin Lab)

We believe these observations warrant a comprehensive search for activated tyrosine kinases in myeloproliferative disorders and hematological malignancies, as there are likely additional unidentified genetic events with biological and therapeutic significance. Additional in vitro and in vivo studies are needed to determine the cause of the specificity of JAK2 V617F for myeloid and lymphoid diseases.

11 days ago

Journal

JAK2 (Janus kinase 2)

JAK2 V617F • JAK2 mutation

11d

Case report: Successful use of ruxolitinib to treat interstitial pneumonia as an unusual primary presentation in primary myelofibrosis-two birds with one stone. (PubMed, Front Oncol)

Anemia and interstitial pneumonia both significantly improved following treatment with a Janus kinase 2 gene inhibitor. In this report, we discuss the possible mechanisms underlying PMF complicated with ILD.

11 days ago

Journal

JAK2 (Janus kinase 2)

Jakafi (ruxolitinib)

11d

JAK2-V617F mutation among blood donors: A meta-analysis. (PubMed, Saudi Med J)

The prevalence of the JAK2 mutation among blood donors is similar to the general population's but slightly higher among repeat donors with elevated hematocrit. Further research is necessary to establish definitive upper hemoglobin limits for donor deferral.PROSPERO No.: CRD42023456878.

11 days ago

Clinical • Retrospective data • Review • Journal

JAK2 (Janus kinase 2)

JAK2 V617F • JAK2 mutation

12d

Polycythemia vera with acute coronary syndrome and bleeding as initial presentation: A case report and literature review. (PubMed, Radiol Case Rep)

This case highlights the importance of considering myeloproliferative disorders in patients with atypical thrombotic and hemorrhagic events. It emphasizes the need for early diagnosis and appropriate treatment to optimize patient outcomes.

12 days ago

Review • Journal

JAK2 (Janus kinase 2)

JAK2 V617F • JAK2 mutation

14d

Through thick and thin: confronting the aggressive cutaneous T-cell lymphomas. (PubMed, Hematology Am Soc Hematol Educ Program)

In contrast to MF/SS, PCAETCL and PCGDTCL remain diseases with few prospective studies to guide treatment. However, recent genomic insights on these diseases, such as the presence of JAK2 fusions in PCAETCL and cell of origin findings in PCGDTCL, have created options for new biomarker-driven strategies.

14 days ago

Review • Journal

JAK2 (Janus kinase 2) • CD8 (cluster of differentiation 8)

JAK2 fusion

14d

The spectrum of Ph-negative disease: CNL and CSF3R-related disorders. (PubMed, Hematology Am Soc Hematol Educ Program)

Pitfalls in diagnosis include subjectivity in assessing neutrophil dysplasia and distinguishing true neoplastic neutrophilia from reactive neutrophilias that may be superimposed upon or occur as a manifestation of the progression of other myeloid neoplasms. Accurate distinction between neutrophilic myeloid neoplasms is important, as it helps guide patient management and may disclose specific genetic lesions amenable to targeted therapy.

14 days ago

Review • Journal

ABL1 (ABL proto-oncogene 1) • JAK2 (Janus kinase 2) • CSF3R (Colony Stimulating Factor 3 Receptor) • CALR (Calreticulin)

CALR mutation • CSF3R mutation

15d

SF3B1 Gene Mutations and Their Significance for Patients with Myelodysplastic Neoplasms (MDS) (ASH 2024)

Three are still alive and are undergoing azacitidine treatment at 6.5, 8.5, and 21 months after their diagnosis.Identification of splicing factor gene mutations is an important diagnostic tool for the stratification of MDS patients...Other biological factors such as the mutation variant, association with complex karyotypes, and mutations in other genes, may also affect the prognosis of patients with mutated SF3B1. Therefore, a comprehensive view that includes all cytogenomic, molecular, and clinical data is important for accurate diagnosis and personalized treatment of MDS patients.Supported by MH CZ-DRO 0064165

15 days ago

Clinical

TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • DNMT3A (DNA methyltransferase 1) • JAK2 (Janus kinase 2) • RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • STAG2 (Stromal Antigen 2) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2) • BCORL1 (BCL6 Corepressor Like 1)

TP53 mutation • NRAS mutation • TET2 mutation • SF3B1 mutation • SRSF2 mutation • U2AF1 mutation • Chr del(5q) • SF3B1 K666N • SF3B1 K700E

Archer® VariantPlex® Myeloid panel

azacitidine

16d

Leukemia inhibitory factor (LIF) receptor amplifies pathogenic activation of fibroblasts in lung fibrosis. (PubMed, Proc Natl Acad Sci U S A)

Together, we find that LIFR drives an autocrine circuit that amplifies and sustains pathogenic activation of IPF fibroblasts. Targeting a single, downstream master amplifier on fibroblasts, like LIFR, is an alternative therapeutic strategy that simultaneously attenuates the profibrotic effects of multiple upstream stimuli.

16 days ago

Journal

JAK2 (Janus kinase 2) • LIFR (LIF Receptor Subunit Alpha) • TGFB1 (Transforming Growth Factor Beta 1) • STAT1 (Signal Transducer And Activator Of Transcription 1) • IL13 (Interleukin 13) • IL4 (Interleukin 4) • LIF (LIF Interleukin 6 Family Cytokine)

17d

JAK2/ULK1 axis promotes cervical cancer progression by autophagy induction and SRPK1 phosphorylation. (PubMed, Oncogene)

Furthermore, we identified SRPK1 as a potential downstream substrate of ULK1 to promote the progression of CCa. Our research sheds light on the molecular mechanism of CCa progression, through JAK2/ULK1 axis, and emphasizes the phosphorylation of ULK1 at Y1007 as a predictor of CCa.

17 days ago

Journal

JAK2 (Janus kinase 2) • SRPK1 (SRSF Protein Kinase 1)

18d

Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications (VYP) (clinicaltrials.gov)

P=N/A, N=200, Recruiting, University Hospital, Brest

18 days ago

New trial

JAK2 (Janus kinase 2) • CALR (Calreticulin)

CALR mutation

19d

Exploring the mechanism of Jianpi Lishi Jiedu Granules against postoperative recurrence of colorectal adenoma based on IL-6/JAK/STAT3 signaling pathway. (PubMed, Cell Signal)

JLJG was found to effectively modulate the expression levels of these proteins, as well as the expression of downstream genes including BCL2, MCL1, P21, and JAK1, STAT3, thereby inhibiting the IL-6/JAK/STAT3 signaling pathway. Consequently, this study demonstrates that JLJG prevents the postoperative recurrence of CRA by inhibiting the IL-6/JAK/STAT3 signaling pathway and its negative feedback loops.

19 days ago

Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • JAK2 (Janus kinase 2) • CCND1 (Cyclin D1) • MCL1 (Myeloid cell leukemia 1) • IL6 (Interleukin 6) • BCL2L1 (BCL2-like 1) • JAK1 (Janus Kinase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • SOCS3 (Suppressor Of Cytokine Signaling 3)

BCL2 expression • MCL1 expression

20d

A novel in silico approach for identifying multi-target JAK/STAT inhibitors as anticancer agents. (PubMed, J Mol Graph Model)

Subsequently, Molecular Docking studies are conducted on JAK2, JAK3, and STAT3, facilitating the identification of the most promising compound, 755435. Finally, Molecular Dynamics Simulations validate the high stability of the potential multitarget inhibitor 755435 in complex with JAK2, JAK3, and STAT3.

20 days ago

Journal

JAK2 (Janus kinase 2) • TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • JAK3 (Janus Kinase 3)

23d

Molecular Profile of BCR-ABL1 Negative Myeloproliferative Neoplasm in a Moroccan Population. (PubMed, Asian Pac J Cancer Prev)

In conclusion, our study provides valuable insights into the prevalence and characteristics of JAK2, CALR, and MPL mutations in BCR-ABL1 negative MPNs in the Moroccan population, highlighting the importance of genetic characterization to optimize the clinical management of these diseases.

23 days ago

Journal

ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • JAK2 (Janus kinase 2) • CALR (Calreticulin) • STAT5A (Signal Transducer And Activator Of Transcription 5A) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)

JAK2 V617F • JAK2 mutation • CALR mutation • STAT5A mutation

24d

Network pharmacology, molecular docking, and untargeted metabolomics reveal molecular mechanisms of multi-targets effects of Qingfei Tongluo Plaster improving respiratory syncytial virus pneumonia. (PubMed, Chin Herb Med)

A total of 28 metabolites underwent significant changes in the QFP treatment, and there are four metabolic pathways consistent with the KEGG pathway analyzed by network pharmacology, suggesting that they may be critical processes related to treatment. These results provide essential perspicacity into the mechanisms of action of QFP as a promising anti-RSV drug.

24 days ago

Journal • Metabolomic study

EGFR (Epidermal growth factor receptor) • JAK2 (Janus kinase 2) • CCND1 (Cyclin D1) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • STAT3 (Signal Transducer And Activator Of Transcription 3) • IL17A (Interleukin 17A) • STAT1 (Signal Transducer And Activator Of Transcription 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • NOS2 (Nitric Oxide Synthase 2) • FOS (Fos Proto-Oncogene AP-1 Transcription Factor Subunit 2) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • MAPK14 (Mitogen-Activated Protein Kinase 14) • MAPK3 (Mitogen-Activated Protein Kinase 3) • RELA (RELA Proto-Oncogene)

24d

Chromosome-level genome assembly of Iodes seguinii and its metabonomic implications for rheumatoid arthritis treatment. (PubMed, Plant Genome)

The discovery of luteolin, in particular, underscores its potential therapeutic role. These findings provide a valuable genomic resource and a scientific basis for the development and application of I. seguinii, addressing the genomic gap in the genus Iodes and the order Icacinales and underscoring the need for further research in genomics, transcriptomics, and metabolomics to fully explore its potential.

24 days ago

Journal • IO biomarker

EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • JAK2 (Janus kinase 2) • TNFA (Tumor Necrosis Factor-Alpha) • MAPK1 (Mitogen-activated protein kinase 1) • SYK (Spleen tyrosine kinase) • TLR4 (Toll Like Receptor 4)

24d

Cryptotanshinone Suppresses the STAT3/BCL-2 Pathway to Provoke Human Bladder Urothelial Carcinoma Cell Death. (PubMed, Environ Toxicol)

Altogether, we conclude that the blockade of the JAK2/STAT3/BCL-2 antiapoptotic signaling axis is a vital mechanism whereby CTS provokes bladder cancer cytotoxicity. The current evidence implicates CTS's potential to be translated into a bladder cancer therapeutic agent.

24 days ago

Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • JAK2 (Janus kinase 2) • IL6 (Interleukin 6) • STAT3 (Signal Transducer And Activator Of Transcription 3)

STAT3 mutation

24d

Myeloproliferative Neoplasms: Challenging Dogma. (PubMed, J Clin Med)

Linked to these disputes is another: whether therapy with hydroxyurea promotes acute leukemia in disorders with a substantial possibility of longevity...Most of these changes, however, conflicted with prior well-validated, phenotypically driven diagnostic criteria and the management of these disorders. The aim of this review is to examine these conflicts and demonstrate how genomic discoveries in myeloproliferative neoplasms can be used to effectively complement the known phenotypic features of these disorders for their diagnosis and management.

24 days ago

Review • Journal

JAK2 (Janus kinase 2) • CALR (Calreticulin)

hydroxyurea

25d

In Silico Analysis of Non-Conventional Oxidative Stress-Related Enzymes and Their Potential Relationship with Carcinogenesis. (PubMed, Antioxidants (Basel))

OSRE also interact with key oncogenic signaling pathways, including Wnt/β-catenin and JAK2/STAT3, linking them to cancer aggressiveness and therapeutic resistance. Future research should focus on translating these findings into clinical applications, including the development of novel inhibitors or drugs targeting these non-classical enzymes.

25 days ago

Journal

EGFR (Epidermal growth factor receptor) • JAK2 (Janus kinase 2) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • PLCG2 (Phospholipase C Gamma 2) • CAT (Catalase)

25d

Recurrent PAX5::ZCCHC7 rearrangement in B-cell acute lymphoblastic leukemia. (PubMed, Ann Hematol)

In summary, the PAX5::ZCCHC7 is a recurrent genetic aberration in B-ALL and seems to act as an additional genetic abnormality of subtype-defining aberration. Whether the PAX5::ZCCHC7 could act as a leukemia-initiating event or not needs further investigation.

25 days ago

Journal

ABL1 (ABL proto-oncogene 1) • JAK2 (Janus kinase 2) • RUNX1 (RUNX Family Transcription Factor 1) • ETV6 (ETS Variant Transcription Factor 6) • CRLF2 (Cytokine Receptor Like Factor 2) • PAX5 (Paired Box 5) • TCF3 (Transcription Factor 3)

PAX5 deletion

26d

Survey for Activating Oncogenic Mutation Variants in Metazoan Germline Genes. (PubMed, J Mol Evol)

While cancer expansion ensues from dysregulated growth elicited by these mutations, this effect is likely detrimental to embryonic development and/or survival of multicellular organisms. Although all oncogenic mutations considered here are gain-of-function where five of the six increase activity of the encoded proteins, clonal advancement promotes tumor growth by these genomic changes without conferring selection advantages benefiting the organism or species.

26 days ago

Journal

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • JAK2 (Janus kinase 2)

EGFR mutation • BRAF mutation • PIK3CA mutation

29d

Distinct epigenetic and transcriptional profiles of Epstein-Barr virus (EBV) positive and negative primary CNS lymphomas. (PubMed, Neuro Oncol)

EBV+ and EBV- PCNSL harbor distinct transcriptional and epigenetic profiles, corroborating them as distinctive biological subtypes. Uncovered differences provide novel insights into their pathobiology, may guide molecular diagnostics and targeted therapies.

29 days ago

Journal

JAK2 (Janus kinase 2) • CD79B (CD79b Molecule) • IL10 (Interleukin 10) • SYK (Spleen tyrosine kinase) • FCER2 (Fc Fragment Of IgE Receptor II)

PU-H71 (NSC 750424): a molecular masterpiece that targets HSP90 in cancer and beyond. (PubMed, Front Pharmacol)

Additionally, the present report also suggests the promising role of PU-H71 in JAK2-dependent myeloproliferative neoplasms. Eventually, our report sheds more light on the multiple functions of HSP90 protein as well as the potential therapeutic benefit of its selective inhibitor PU-H71 in the context of an array of diseases, laying the foundations for the development of novel therapeutic approaches that could achieve better treatment outcomes.

1 month ago

Review • Journal

EGFR (Epidermal growth factor receptor) • JAK2 (Janus kinase 2) • BCL6 (B-cell CLL/lymphoma 6) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • HSP90AB1 (Heat Shock Protein 90 Alpha Family Class B Member 1)

zelavespib intravenous (PU-H71 IV)

Prolactin-specific induction of the nuclear translocation of porcine prolactin receptor in porcine mammary epithelial cells. (PubMed, Tissue Cell)

Additionally, we discovered that the nuclear translocation of the pPRL-PRLR complex is influenced by importin β1 (IMP β1), and EEA1 was involved in the nuclear translocation of pPRL-PRLR complex. In cell nuclei, the pPRL-PRLR complex has the potential to form a pPRL-PRLR-JAK2 multimer complex, suggesting that the nuclear-localized pPRL-PRLR complex may remain capable of transmitting signals, analogous to its function in the cell membrane.

1 month ago

Preclinical • Journal

JAK2 (Janus kinase 2) • PRLR (Prolactin Receptor 2)

Efficacy of Daratumumab-Based Regimens for Extramedullary Pulmonary Plasmacytoma: A Case Report. (PubMed, Cancer Rep (Hoboken))

We showed the efficacy of daratumumab in combination with targeted therapies for the treatment of pulmonary MM.

1 month ago

Journal

JAK2 (Janus kinase 2)

JAK2 mutation

Darzalex (daratumumab)

Diagnosis and Treatment of Polycythemia Vera: A Review. (PubMed, JAMA)

Ruxolitinib is a Janus kinase inhibitor that can alleviate pruritus and decrease splenomegaly in patients who are intolerant of or resistant to hydroxyurea. To decrease the risk of thrombosis, all patients with PV should be treated with aspirin and therapeutic phlebotomy to maintain a hematocrit of less than 45%. Cytoreductive therapies, such as hydroxyurea or interferon, are recommended for patients at high risk of thrombosis.

1 month ago

Review • Journal

JAK2 (Janus kinase 2)

Jakafi (ruxolitinib) • hydroxyurea • aspirin

Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis. (PubMed, J Hematol Oncol)

In a multivariate analysis, grade 2-3 MF (HR 2.0, 95%CI 1.59-2.51) was the strongest prognostic factor for survival. In summary, grade 2-3 MF in AML is associated with worse outcomes.

1 month ago

Retrospective data • Journal

IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • JAK2 (Janus kinase 2) • CEBPA (CCAAT Enhancer Binding Protein Alpha)

JAK2 mutation

Insight into the molecular mechanism of anti-breast cancer therapeutic potential of substituted salicylidene-based compounds using cell-based assays and molecular docking studies. (PubMed, Eur J Pharmacol)

Molecular docking studies revealed that selected protein targets strongly interact with bioactive compounds, and the estimated inhibition constants (Ki) of JAK2, STAT3, COX-2, HPV31 E6, EGFR1, TP53, and PARP1 were significantly decreased compared to acetylsalicylic acid. This could be a clear indication that these protein targets are implicated with antiproliferative efficacy, thereby warranting the potential of (1) and (7) to be used as anti-breast cancer drug candidates.

1 month ago

Journal • PARP Biomarker

TP53 (Tumor protein P53) • JAK2 (Janus kinase 2) • STAT3 (Signal Transducer And Activator Of Transcription 3) • PARP1 (Poly(ADP-Ribose) Polymerase 1)

TP53 expression

aspirin

Harnessing Tumor Cell-Derived Exosomes for Immune Rejection Management in Corneal Transplantation. (PubMed, Adv Sci (Weinh))

Proteomic analyses reveal differential expression of pivotal proteins in B16-Exo, notably the JAK2 protein within the JAK-STAT signaling pathway, which has been mechanistically demonstrated to amplify the activity of myeloid-derived suppressor cells (MDSCs) and inhibit T cell proliferation. These findings demonstrate the significant immunomodulatory effect of B16-Exo in transplant immunology, supporting the continued exploration of tumor-derived exosomes as a platform to uncover novel immunosuppressive mechanisms in transplantation.

1 month ago

Journal • Tumor cell

JAK2 (Janus kinase 2)

High CTLA-4 gene expression is an independent good prognosis factor in breast cancer patients, especially in the HER2-enriched subtype. (PubMed, Cancer Cell Int)

Considering all these data, we can conclude that the expression of immunoregulatory genes depends on tumor phenotype and has potential clinical implications in BC patients.

1 month ago

Journal • PD(L)-1 Biomarker • IO biomarker

HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • JAK2 (Janus kinase 2) • PD-1 (Programmed cell death 1) • CD276 (CD276 Molecule) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • PD-L2 (Programmed Cell Death 1 Ligand 2)

HER-2 positive • HER-2 negative • PD-1 expression • CTLA4 expression • PD-L2 expression

Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib. (PubMed, Clin Lymphoma Myeloma Leuk)

These novel time-dependent transfusion burden analyses demonstrate that momelotinib is associated with anemia-related benefits in most patients and greater transfusion burden reduction versus comparators.

1 month ago

Journal

JAK2 (Janus kinase 2) • ACVR1 (Activin A Receptor Type 1)

Jakafi (ruxolitinib) • Ojjaara (momelotinib)